Výsledky vyhledávání - "Tom Ashhurst"

Akademický článek

Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID

Autor: Sander W Tas, Joep Killestein, Joost Raaphorst, Taco W Kuijpers, Alexandre E Voskuyl, Gertjan Wolbink, Theo Rispens, Anneke J van der Kooi, Anja Ten Brinke, Karina de Leeuw, Abraham Rutgers, Juan J Garcia-Vallejo, Frederike J Bemelman, YK Onno Teng, Phyllis I Spuls, Mark Löwenberg, Jelle de Wit, Diane van der Woude, Marcel W Bekkenk, Luuk Wieske, Esther Brusse, Laura Boekel, Filip Eftimov, Eileen W Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Koos P J van Dam, Adriaan G Volkers, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Bo Broens, Barbara Horváth, Annabel M Ruiter, Matthias H Busch, Dirk Jan Hijnen, Niels J M Verstegen, Pieter A van Doorn, Jan JGM Verschuuren, Laura Y L Kummer, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Mariël C Duurland, Veronique A L Konijn, Carolien E van de Sandt, Laura Fernández Blanco, Amélie Bos, Charlotte Menage, Tineke Jorritsma, Jet van den Dijssel, Rivka de Jongh, Tom Ashhurst, Marit J van Gils, Mathieu Claireaux, Sija Marieke van Ham, Renée CF van Allaart, Adája E Baars, George Elias, Cécile ACM van Els, H Stephan Goedee, Geert RAM D’Haens, Papay BP Jallah, Elham S Mirfazeli, Jim BD Keijser, Lotte van Ouwerkerk, Pieter van Paassen, Agner R Parra Sanchez, W Ludo van der Pol, Corine RG Schreurs, R Bart Takkenberg, Koos AH Zwinderman

Publikováno v: RMD Open, Vol 10, Iss 4 (2024)

Objectives Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerabi

Externí odkaz: https://doaj.org/article/afff65e4600e4deabe9d42545d2637c0

Zobrazit plný text záznamu

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants

Autor: Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, Laura Y L Kummer, Maurice Steenhuis, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Erik H Vogelzang, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Martijn Gerritsen, Irene E van der Horst-Bruinsma, Willem F Lems, Mike T Nurmohamed, Maarten Boers, Sofie Keijzer, Jim Keijser, Carolien van de Sandt, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Theo Rispens, Taco W Kuijpers, Gertjan Wolbink, Filip Eftimov, Rivka de Jongh, Lisan Kuijper, Mariel Duurland, Ruth Hagen, Jet van den Dijssel, Christine Kreher, Amelie Bos, Viriginia Palomares Cabeza, Veronique Konijn, George Elias, Juan Vallejo, Marrit van Gils, Tom Ashhurst, Sergey Nejentsev, Elham Mirfazeli

Publikováno v: The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier

Contains fulltext : 251784.pdf (Publisher’s version ) (Closed access) BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with imm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3619c889e4bb633a950bf507234c28e5
https://hdl.handle.net/11245.1/f610fc44-105d-4e73-957e-813043c700aa

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání